Pacific Edge Ltd (peb) Logo

Pacific Edge Ltd (PEB)

___:___ · Healthcare

PEB Chart


PEB's Principal Activity is the development and deployment of specialist cancer diagnostics tools.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -54.42%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 415 of 2,416
Sector Rank 25 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies EHE / SIG / OCA
EPS -$0.022
DPS $0.00
Book Value Per Share $0.00

Broker Consensus

PEB is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Pacific Edge Limited (PEB) is a cancer diagnostics company. It is being in to discovering, building and commercialising innovative cancer diagnostic tests that can contribute to a clinically meaningful difference in the detection and management of cancer.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Dunedin New Zealand 9016
Registry Link Market Services
Auditor PricewaterhouseCoopers
Date Listed 27 Sep 2021

Upcoming Calendar (Forecasted)

Date Event
24/11/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Tony Barclay Non-Executive Director Mar 2022

Mr Tony Barclay

Non-Executive Director

Mr Barclay is an experienced healthcare industry executive and has experience in corporate finance and healthcare technology companies. He was formerly Chief Financial Officer and Company Secretary of Fisher & Paykel Healthcare (FPH) from when the healthcare business was separated from Fisher & Paykel Appliances in 2001. From then he led the finance team and was a member of the senior leadership team until 2018. He is currently Independent Chair of Izon Science, a Christchurch-based manufacturer of nano-biological separation and characterisation tools and Chair of Australian-based Baymatob, a company involved in women's health and AI-guided monitoring for pregnancy and labour. He is also an Independent Director of Veriphi, an Auckland-based technology company developing intravenous drug identity and concentration verification devices.

Dr Peter Meintjes Chief Executive Officer Jan 2022
Mr Anatole Masfen Non-Executive Director N/A

Mr Anatole Masfen

Non-Executive Director

Mr Masfen is the co-founder of Artemis Capital, a private equity investment firm based in Auckland. He has spent eight years with Air New Zealand (and later the merged entity with Ansett Australia) holding senior positions in Pricing, Revenue Management and Systems implementation. He holds directorships in numerous private companies and has knowledge of financial capital markets. He also has a detailed knowledge of the medical sector and future trends. In particular human sciences and disruptive technologies. He is also a Chair of Capital Committee and member of Risk committee.

Dr Bryan Raymond George Williams Non-Executive Director N/A

Dr Bryan Raymond George Williams

Non-Executive Director

Dr Williams is an internationally recognised cancer researcher and research administrator, with business experience. He has held a number of governance roles, including with a NASDAQ listed biotech company. Presently, he serves on the Board of two privately held Australian biotechnology companies. He was Director and CEO of the Hudson Institute of Medical Research. He is currently Emeritus Director and Distinguished Scientist at the Hudson Institute in Melbourne.

Mr Christopher (Chris) John Gallaher Non-Executive Chairman,Non-Executive Director N/A

Mr Christopher (Chris) John Gallaher

Non-Executive Chairman,Non-Executive Director

Mr Gallaher has held senior positions in both CEO and CFO roles with a number of international companies and was a partner in Arthur Young, Chartered Accountants. Prior to retiring from full time corporate life, he was CFO of Fulton Hogan, a NZ resources based civil contractor. He is also Chairman of Mariposa Holdings, a charitable organisation. He is also a member of Risk & Capital committee.

Ms Sarah Natalie Park Non-Executive Director N/A

Ms Sarah Natalie Park

Non-Executive Director

Ms Park has international corporate finance experience with PricewaterhouseCoopers in New Zealand and HSBC Investment Bank in London. During her executive career, she worked in M&A, equity capital markets and was previously an Equity Research Analyst. She also had a lead role in seeking private capital from Asia, the Middle East and Europe for early-stage US biopharmaceutical companies. Ms Park is a Director of National Provident Fund and Hawke's Bay Airport. She has a focus on providing her Audit & Risk capability and experience to her directorship portfolio. She is also chair of Risk Committee and a member of Capital Committee.

Ms Anna Kate Stove Non-Executive Director N/A

Ms Anna Kate Stove

Non-Executive Director

Ms Stove has a 25+ year track record in leading and driving transformational change within the pharmaceutical sector. She has Global business experience having held a variety of senior executive roles within NZ, Asia Pacific and Europe. She recently retired from being NZ General Manager at GlaxoSmthKline & she is now committed to growing businesses through best practice governance. She is currently the Chair of Global Women, Director of TAB NZ & Director of Rua Bioscience.

Mr Mark Green Non-Executive Director N/A

Mr Mark Green

Non-Executive Director

Mr Green is an experienced corporate finance professional, with 25 years of experience in the Australasian capital, corporate and financial markets. He was an Executive Director for Investment Banking at Goldman Sachs where he worked for nearly 20 years and has been involved in many New Zealand transactions including the IPOs of Meridian, Mighty River Power and Vector. He is a Director of a number of entities including being Chair of Astrolab VC Investment Committee and a Director of Mariposa Holdings (a charitable organisation).

Mr Grant Edward Gibson Chief Financial Officer,Company Secretary N/A
Peter Meintjes Chief Executive Officer N/A

Director Transactions

PEB directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
21/04/22 David Darling Issued 92,985 $1.00 $92,985 Issue of securities
20/10/21 David Darling Issued 37,037 $1.35 $50,000 Rights issue
05/10/21 David Darling Sell +139,478 $1.426 ($198,838) On-market trade

Director Interests

The current holdings of PEB directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Mark Green N/A N/A N/A N/A N/A
Anna Stove N/A N/A N/A N/A N/A
Sarah Park N/A N/A N/A N/A N/A
Christopher (Chris) Gallaher N/A N/A N/A N/A N/A
Bryan Williams N/A N/A N/A N/A N/A
Anatole Masfen N/A N/A N/A N/A N/A
Tony Barclay N/A N/A N/A N/A N/A

Shareholder Info

Substantial Shareholders

No Substantial Shareholders for PEB in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
No Financial Year End data available
PEB Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.